| Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016 AJ Cowan, C Allen, A Barac, H Basaleem, I Bensenor, MP Curado, ... JAMA oncology 4 (9), 1221-1227, 2018 | 642 | 2018 |
| Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial PM Voorhees, JL Kaufman, J Laubach, DW Sborov, B Reeves, ... Blood, The Journal of the American Society of Hematology 136 (8), 936-945, 2020 | 640 | 2020 |
| Diagnosis and management of multiple myeloma: a review AJ Cowan, DJ Green, M Kwok, S Lee, DG Coffey, LA Holmberg, S Tuazon, ... Jama 327 (5), 464-477, 2022 | 519 | 2022 |
| γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma MJ Pont, T Hill, GO Cole, JJ Abbott, J Kelliher, AI Salter, M Hudecek, ... Blood, The Journal of the American Society of Hematology 134 (19), 1585-1597, 2019 | 277 | 2019 |
| Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience AJ Cowan, M Skinner, DC Seldin, JL Berk, DR Lichtenstein, CJ O'Hara, ... Haematologica 98 (1), 141, 2013 | 214 | 2013 |
| Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies J Gauthier, ED Bezerra, AV Hirayama, S Fiorenza, A Sheih, CK Chou, ... Blood, The Journal of the American Society of Hematology 137 (3), 323-335, 2021 | 124 | 2021 |
| Fully human Bcma targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma DJ Green, M Pont, BD Sather, AJ Cowan, CJ Turtle, BG Till, ... Blood 132 (Supplement 1), 1011-1011, 2018 | 114 | 2018 |
| Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy SD Smith, BG Till, MS Shadman, RC Lynch, AJ Cowan, QV Wu, ... British journal of haematology 189 (6), 1119-1126, 2020 | 92 | 2020 |
| Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin AJ Cowan, GS Laszlo, EH Estey, RB Walter Frontiers in bioscience (Landmark edition) 18, 1311, 2013 | 70 | 2013 |
| Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory … AJ Cowan, M Pont, BD Sather, CJ Turtle, BG Till, AM Nagengast, ... Blood 134, 204, 2019 | 61 | 2019 |
| Safety and activity of brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory (Rel/Ref) classical Hodgkin lymphoma (cHL): initial … RD Cassaday, J Fromm, AJ Cowan, EN Libby III, M Philip, S Behnia, ... Blood 128 (22), 1834, 2016 | 56 | 2016 |
| Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed … PM Voorhees, JL Kaufman, JP Laubach, DW Sborov, B Reeves, ... Blood 134, 691, 2019 | 50 | 2019 |
| HemOnc. org: A collaborative online knowledge platform for oncology professionals JL Warner, AJ Cowan, AC Hall, PC Yang Journal of Oncology Practice 11 (3), e336-e350, 2015 | 48 | 2015 |
| Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies CS Walti, EM Krantz, J Maalouf, J Boonyaratanakornkit, J Keane-Candib, ... JCI insight 6 (11), 2021 | 46 | 2021 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of … JL Kaufman, JP Laubach, D Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 136, 45-46, 2020 | 46 | 2020 |
| Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of … PM Voorhees, DW Sborov, J Laubach, JL Kaufman, B Reeves, ... The Lancet Haematology 10 (10), e825-e837, 2023 | 45 | 2023 |
| Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre … RC Lynch, RD Cassaday, SD Smith, JR Fromm, AJ Cowan, EH Warren, ... The lancet haematology 8 (8), e562-e571, 2021 | 42 | 2021 |
| Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission AJ Cowan, PA Stevenson, RD Cassaday, SA Graf, JR Fromm, D Wu, ... Biology of Blood and Marrow Transplantation 22 (2), 380-385, 2016 | 41 | 2016 |
| Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis … JP Laubach, JL Kaufman, DW Sborov, B Reeves, C Rodriguez, A Chari, ... Blood 138, 79, 2021 | 39 | 2021 |
| Stem cell mobilization yields with daratumumab-and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and … S Chhabra, N Callander, NL Watts, LJ Costa, B Thapa, JL Kaufman, ... Transplantation and Cellular Therapy 29 (3), 174. e1-174. e10, 2023 | 36 | 2023 |
